David Dai
Stock Analyst at UBS
(0.93)
# 3,906
Out of 5,042 analysts
26
Total ratings
39.13%
Success rate
-11.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Downgrades: Neutral | $72 → $97 | $94.88 | +2.23% | 2 | Sep 30, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $10.78 | +85.53% | 1 | Sep 23, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $37 → $35 | $13.53 | +158.68% | 2 | Jul 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $11.09 | +134.45% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $19.28 | +55.60% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.25 | -11.11% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $7.76 | +209.28% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $93.39 | +7.08% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $9.70 | +44.33% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $33.18 | -27.67% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.99 | +568.90% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $24.90 | +177.11% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $29.18 | +71.35% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $43.67 | +37.39% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.89 | +3,046.07% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $57.29 | -30.18% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.84 | +2,073.91% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.41 | +1,974.69% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $33.19 | +56.67% | 1 | Mar 17, 2020 |
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $72 → $97
Current: $94.88
Upside: +2.23%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $10.78
Upside: +85.53%
Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37 → $35
Current: $13.53
Upside: +158.68%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $11.09
Upside: +134.45%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $19.28
Upside: +55.60%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.25
Upside: -11.11%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $7.76
Upside: +209.28%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $93.39
Upside: +7.08%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $9.70
Upside: +44.33%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $33.18
Upside: -27.67%
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.99
Upside: +568.90%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $24.90
Upside: +177.11%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $29.18
Upside: +71.35%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $43.67
Upside: +37.39%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.89
Upside: +3,046.07%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $57.29
Upside: -30.18%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.84
Upside: +2,073.91%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.41
Upside: +1,974.69%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $33.19
Upside: +56.67%